NCT02319941 (OPTIMA) is a Phase 2 clinical trial of ticagrelor in Acute Coronary Syndrome, sponsored by Seung-Jung Park.

Who is sponsoring NCT02319941?

NCT02319941 is sponsored by Seung-Jung Park.

What drugs are being tested in NCT02319941?

Interventions in NCT02319941: ticagrelor, clopidogrel.

What condition does NCT02319941 study?

NCT02319941 studies Acute Coronary Syndrome.

Is NCT02319941 still recruiting?

NCT02319941 is currently completed. Last updated 16 June 2017.

Last reviewed 2017-06-16 · How we verify

NCT02319941: OPTIMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Completed Phase 2 Last updated 16 June 2017

What this trial tests

Phase 2 trial testing ticagrelor in Acute Coronary Syndrome in 65 participants. Completed in 10 March 2017.

Timeline

20 May 2015

Primary endpoint
14 February 2017

10 March 2017

Quick facts

Lead sponsor	Seung-Jung Park
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	65
Start date	20 May 2015
Primary completion	14 February 2017
Estimated completion	10 March 2017
Sites	1 location across South Korea

Drugs / interventions tested

ticagrelor (ticagrelor) — full drug profile →
clopidogrel (clopidogrel) — full drug profile →

Conditions studied

Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →

Sponsor

Seung-Jung Park — full company profile →

Who can join

Adults 20 to 80, any sex, with Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients with Acute Coronary Syndromes

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ticagrelor

Trials testing the same drug.

NCT04006288 — Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary · Phase 4 · completed
NCT03381742 — Efficacy and Safety of Low-dose Ticagrelor · Phase 2, PHASE3 · completed
NCT03062462 — Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platel · Phase 2, PHASE3 · unknown
NCT01994720 — [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] · Phase 3 · completed
NCT02022748 — Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects · Phase 1 · completed

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting

Other Seung-Jung Park trials

Trials by the same sponsor.

NCT06908499 — The DECISION-CTO Extended 10 Y Follow-up · not yet recruiting
NCT06177743 — IRIS-Coroflex NEO Cohort · recruiting
NCT05125367 — Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation i · completed
NCT03967158 — Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice · active not recruiting
NCT03190057 — IRIS-BioFreedom Cohort in the IRIS-DES Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02319941 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seung-Jung Park
Last refreshed: 16 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02319941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing